Cerenome (CNSY)
Diagnostic testing and targeted radiotherapy development for central nervous system cancers.
Something off on this page? Send us feedback.
Provides CNSide cerebrospinal-fluid cancer testing and is developing REYOBIQ targeted radiotherapy for central nervous system tumors. The integrated model pairs diagnostics, clinical development and an emerging data and AI layer, with revenue shaped by grant funding, reimbursement and future regulatory outcomes.
Combines CNSide, a cerebrospinal-fluid diagnostic testing service for detecting and characterizing tumor cells in leptomeningeal metastases, with REYOBIQ, an investigational injectable radiotherapeutic for CNS tumors. CNSide is ordered by U.S. healthcare professionals through a Houston laboratory, while REYOBIQ is being studied for leptomeningeal metastases, recurrent glioblastoma and pediatric brain cancers.
Builds a data and AI initiative intended to connect diagnostic, molecular, imaging and clinical data for precision-oncology workflows and therapeutic development. Revenue currently includes grant reimbursement and prospective diagnostic collections; therapeutic revenue depends on clinical results and approval. Operations are U.S.-centered and depend on test ordering, reimbursement, laboratory licensing, outside manufacturing and continued financing.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.6M · Total debt $44.0K · Total assets $14.0M · Shareholders' equity $5.5M
- Revenue
- $411.0K
- Operating income
- −$9.1M
- Net income
- −$9.0M
No dividends on record.
Unavailable right now.
Unavailable right now.